T-Cell Non-Hodgkin’s Lymphoma


Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (12-13-2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

Additional Rare Cancer Cases Reported Among Users of TNF Blockers (04-19-2011)

The US Food and Drug Administration (FDA) has received additional reports of a rare type of cancer—hepatosplenic T-cell lymphoma—primarily among adolescents and young adults who are being treated for Crohn’s disease or ulcerative colitis with medications... Continue Reading

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma (12-10-2008)

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma In a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin?s lymphoma) experienced a complete or partial disappearance of detectable... Continue Reading